West Pharmaceutical Services, Inc. (WST) stock analysis
Healthcare · Medical Instruments & Supplies
From the 10-K filed 2026-02-17
How it makes money
It sells primary packaging, containment solutions, and drug delivery systems to pharmaceutical and medical device companies, with international sales representing 56.7% of net sales in 2025.
The company operates through two main segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment sells elastomers, seals, syringes, vials, and self-injection devices primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products segment designs, manufactures, and assembles complex custom devices for pharmaceutical, diagnostic, and medical device customers.
Profitability is driven by manufacturing efficiency, pricing realization, and product mix across its global operations. Sales outside of the U.S. accounted for 56.7% of consolidated net sales in 2025, exposing results to foreign currency fluctuations and international trade policies.
What protects it: the moat
Management claims its competitive advantage rests on product quality, specialized manufacturing expertise, and proprietary containment technologies designed to meet strict pharmaceutical standards.
The company emphasizes its top priority of delivering quality products that meet exact customer specifications and quality standards. Its packaging and containment solutions are engineered to ensure drug compatibility and stability, reduce the risk of glass breakage, and stand up to cold storage environments.
It also relies on an extensive network of technical security controls and regulatory compliance measures to protect its systems and confidential information. However, the filing presents these technological and operational advantages primarily as management's focus rather than demonstrating structural moats against competitors.
What growth costs
The filing does not disclose specific figures for ongoing capital expenditures, research and development investments, or working capital requirements needed to maintain and grow earnings.
While the business discusses maintaining manufacturing facilities across North and South America, Europe, and Asia, alongside analytical lab services and engineering development, the provided text omits specific financial figures for maintenance versus growth investments.
Cost of goods sold includes personnel costs, manufacturing costs, raw materials, freight, depreciation, and facility costs, but exact capital allocation amounts are not specified in the excerpts.
What could damage it
A severe cyberattack or security breach could disrupt manufacturing operations, corrupt proprietary data, and cause substantial financial losses.
The company relies on complex networks and systems for manufacturing, design, and administrative tasks. If unauthorized access or cyberattacks successfully target these systems, operations could face prolonged disruptions or lead to the release of confidential proprietary information.
Such an event would damage customer trust, increase remediation and system modification costs, and impair the company's ability to deliver products efficiently, thereby reducing earnings.
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.